A current model for predicting the risk of cardiovascular diseases in patients with type 2 diabetes mellitus

Cite item

Full Text


Type 2 diabetes mellitus (T2DM) is a severe progressive disease complicating the development of micro- and macrovascular complications that result in early disability, including that in able-bodied persons, a reduction in the patients' life, and its worse quality. The author discusses the new scale developed according to the results of the ADVANCE trial for predicting the cardiovascular risk in patients with T2DM which may be used widely in these patients to estimate the risk of cardiovascular events and as a tool to assist in determining the intensity of treatment. She considers current approaches to treating T2DM, by using the results of the ADVANCE trial.

Full Text

Современная модель прогнозирования риска развития сердечно-сосудистых заболеваний у больных сахарным диабетом 2-го типа. - Аннотация. Сахарный диабет 2-го типа (СД2) - тяжелое прогрессирующее заболевание, осложняющееся развитием микро- и макрососудистых осложнений, которые приводят к ранней инвалидизации, в том числе и лиц трудоспособного возраста, сокращению продолжительности жизни пациентов и ухудшению ее качества. Обсуждается новая шкала прогностического сердечно-сосудистого риска для пациентов с СД2, разработанная по результатам исследования ADVANCE, которая может широко применяться у пациентов с СД2 для количественной оценки риска развития сердечно-сосудистых осложнений и в качестве инструмента, помогающего определить интенсивность лечения. Рассматриваются современные подходы к лечению СД2 с использованием результатов исследования ADVANCE.

About the authors

E V Biriukova

Email: lena@obsudim.ru


  1. Adeghate E., Schatiner P., Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann NY Acad Sci 2006; 1084 (1): 1-29.
  2. Wild S., Roglic A., Green R. et al. Global prevalence of diabetes: estimates for year 2000 and projections for 2030. Diabetes Care 2004; 27 (5): 1047-1053.
  3. Sobel B.E. Optimizing cardiovascular outcomes in diabetes mellitus. Am J Med 2007; 120 (9 Suppl 2): S3-S11.
  4. Zoungas S., Patel A. Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. Ann N Y Acad Sci 2010; 1212 (1): 29-40.
  5. Bartnik M., Ryden L., Ferrari R. et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25 (21): 1880-1890.
  6. Kengne A.P., Patel A., Marre M. et al. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc Prevent Rehab 2011; 18: 393-398.
  7. McFarlane S.I., Banerij M., Sowers J.R. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 713-718.
  8. Milicevic Z., Raz I., Beattie S.D. et al. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 2008; 31 (2): S155-S160.
  9. Bouche J.L., Hurrell D.J. Cardiovascular Disease and Diabetes. Diabet Spectrum 2008; 21 (3): 54-55.
  10. Liebl A., Neiss A., Spannheimer A. et al. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany - results from the CODE-2 study. Exp Clin Enocrinol Diab 2002; 110: 10-16.
  11. Khaled A.A., Sekaran M., Ikram S.I. Type 2 diabetes and vascular complications: A pathophysiologic view. Biomed Res 2010; 21 (2): 147-155.
  12. Dluhy R.G., McMahon G.T. Intensive Glycemic Control in the ACCORD and ADVANCE Trials. N Engl J Med 2008; 358: 2630-2633.
  13. Patel A., MacMahon S., Chalmers J. et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
  14. Stratton I.M., Adler A.I., Neil H.A. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321: 405-412.
  15. Schmitz O., Lund S., Andersen P.H. et al. Optimizing insulin secretogogue therapy in patients with type 2 diabetes. Diabetes Care 2002; 5: 342-346.
  16. Stumvoll M., Goldstein B.J., van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346.
  17. Trovati M., Burzacca S., Mularoni E. et al. Occurrence of low blood glucose concentrations during the afternoon in type 2 (non-insulin-dependent) diabetic patients on oral hypoglycaemic agents: importance of blood glucose monitoring. Diabetologia 1991; 34: 662-667.
  18. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes. (UKPDS 34). Lancet 1998; 352: 837-853.
  19. Jennings P.E. Vascular benefits of gliclazide beyond glycemic control. Metabolism 2000 49: 17-20.
  20. Maddock H.L., Siedlecka S.M., Yellon D.M. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc. Drugs Ther 2004; 18: 113-119.
  21. O'Brien R.C., Luo M., Balazs N. et al. In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications 2000; 14: 201-206.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies